Oncogenes

Journal of Clinical Pathology - Molecular Pathology

Volumn 52, Issue 2, 1999, Pages 55-63

  Wallis, Y L ^a   Macdonald, F ^a  

^a BIRMINGHAM WOMEN S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH FACTOR RECEPTOR; ONCOPROTEIN; TUMOR MARKER;

BREAST CANCER; CARCINOGENESIS; COLORECTAL CANCER; GENE ACTIVATION; HUMAN; LEUKEMIA; LUNG CANCER; MALIGNANT NEOPLASTIC DISEASE; MULTIPLE ENDOCRINE NEOPLASIA; NONHUMAN; ONCOGENE; PANCREAS CANCER; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; STOMACH CANCER; UROGENITAL TRACT CANCER; VIRUS CARCINOGENESIS; VIRUS ONCOGENE; FEMALE; GENE EXPRESSION REGULATION; GENETICS; NEOPLASM; PHYSIOLOGY;

FEMALE; GENE EXPRESSION REGULATION; HUMANS; NEOPLASMS; ONCOGENE PROTEINS; ONCOGENES; TUMOR MARKERS, BIOLOGICAL;

EID: 0033112357     PISSN: 13668714     EISSN: None     Source Type: Journal    
DOI: 10.1136/mp.52.2.55     Document Type: Review

References (55)

1. Duesberg PH, Vogt PK. Differences between the ribonucleic acids of transforming and nontransforming avian tumor viruses. Proc Natl Acad Sci USA 1970;67:1673-80.
2. Stehelin D, Varmus HE, Bishop JM, et al. DNA related to the transforming gene(s) of avian sarcoma viruses is present in normal avian DNA. Nature 1976;260:170-3.
3. Shih C, Shilo BZ, Goldfarb MP, et al. Passage of phenotypes of chemically transformed cells via transfection of DNA and chromatin. Proc Natl Acad Sci USA 1979;76:5714-18.
4. Cooper GM. Cellular transforming genes. Science 1972;217:801-6.
5. Weinberg RA. Oncogenes of spontaneous and chemically induced tumors. Adv Cancer Res 1982;36:140-63.
6. Schwab M, Amler LC. Amplification of cellular oncogenes: a predictor of clinical outcome in human cancer. Genes Chromosomes Cancer 1990;1:181-93.
7. Spencer CA, Groudine M. Control of c-myc regulation in normal and neoplastic cells. Adv Cancer Res 1991;56:1-48.
8. Bos JL. The ras gene family and human carcinogenesis. Mutat Res 1988;195:255-71.
9. Almoguera C, Shibata D, Forrester K, et al. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 1988;53:549-54.
10. Rochlitz CF, Scott GK, Dodson JM, et al. Incidence of activating ras oncogene mutations associated with primary and metastatic human breast cancer. Cancer Res 1989;49:357 60.
11. Portier M, Moles JP, Mazars GR, et al. p53 and RAS gene mutations in multiple myeloma. Oncogene 1992;12:2539 43.
12. Macdonald F, Ford C. Molecular biology of cancer. Bios Scientific Publishers, 1997.
13. Moscatello DK, Holgado-Madruga M, Godwin AK, et al. Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors. Cancer Res 1995;55:5536-9.
14. Proctor AJ, Coombs LM, Cairns JP, et al. Amplification at chromosome 11q13 in transitional cell turnouts of the bladder. Oncogenc 1991;5:789-95.
15. Hajj C, Akoum R, Bradley E, et al. DNA alterations at proto oncogene loci and their clinical significance in operable non-small cell lung cancer. Cancer 1990;66:733-9.
16. Barone MV, Courtneidge SA. Myc but not Fos rescue of PDGF signalling block caused by kinase-inactive Src. Nature 1995;378:509-12.
17. Garcia R, Parikh NU, Saya H, et al. Effect of herbimycin A on growth and pp60c-src activity in human colon tumor cell lines. Oncogene 1991;6:1983-9.
18. Park J, Cartwright CA. Src activity increases and Yes activity decreases during mitosis of human colon carcinoma cells. Mol Cell Biol 1995;15:2374-82.
19. Barnekow A, Paul E, Schartl M. Expression of the c-src protooncogene in human skin tumors. Cancer Res 1987;47:1235-40.
20. Amati B, Land H. Myc-Max-Mad: a transcription factor network controlling cell cycle progression, differentiation and death. Curr Opin Genet Dev 1994;4:102-8.
21. Schwab M, Alitalo K, Klempnauer KH, et al. Amplified DNA with limited homology to myc cellular oncogene is shared by human neuroblastoma cell lines and a neuroblastoma tumour. Nature 1983;305:245-8.
22. Alitalo K, Winqvist R, Lin CC, et al. Aberrant expression of an amplified c-myb oncogene in two cell lines from a colon carcinoma. Proc Natl Acad Sci USA 1984;81:4534-8.
23. Balaban G, Herlyn M, Guerry D, et al. Cytogenetics of human malignant melanoma and premalignant lesions. Cancer Genet Cytogenet 1984;11:429-39.
24. Barletta C, Pelicci PG, Kenyon LC, et al. Relationship between the c-myb locus and the 6q-chromosomal aberration in leukemias and lymphomas. Science 1987;235:1064 7.
25. Guérin M, Sheng ZM, Andrieu N, et al. Strong association between c-myb and oestrogen-receptor expression in human breast cancer. Oncogene 1990;5:131-5.
26. Barletta C, Lazzaro D, Prosperi Porta R, et al. C-MYB activation and the pathogenesis of ovarian cancer. Eur J Gynaccol Oncol 1992;13:53-9.
27. Jiang W, Kahn SM, Tomita N, et al. Amplification and expression of the human cyclin D gene in esophageal cancer. Cancer Res 1992;52:2980-3.
28. Lammie GA, Fanti V, Smith R, et al. D11S287, a putative oncogene on chromosome 11q13, is amplified and expressed in squamous cell and mammary carcinomas and linked to BCL-1. Oncogene 1991;6:439-44.
29. Bigoni R, Negrini M, Veronese ML, et al. Characterization of t(11;14) translocation in mantle cell lymphoma by fluorescent in situ hybridization. Oncogene 1996;13:797-802.
30. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990;61:759-67.
31. Yamashita N, Minamoto T, Ochiai A, et al. Frequent and characteristic K-ras activation in aberrant crypt foci of colon. Is there preference among K-ras mutants for malignant progression? Cancer 1995;75:1527-33.
32. Laurent-Puig P, Olschwang S, Delattre O, et al. Survival and acquired genetic alterations in colorectal cancer. Gastroenterology 1992;4:1136-41.
33. Bell SM, Scott N, Cross D, et al. Prognostic value of p53 overexpression and c-Ki-ras gene mutations in colorectal cancer. Gastroenterology 1993;104:157-64.
34. Finkelstein SD, Sayegh R, Bakker A, et al. Determination of tumor aggressiveness in colorectal cancer by K-ras-2 analysis. Arch Surg 1993;128:526-32.
35. Moerkerk P, Arends JW, van Driel M, et al. Type and number of Ki-ras point mutations relate to stage of human colorectal cancer. Cancer Res 1994;54:3376-8.
36. Sidransky D, Tokino T, Hamilton SR, et al. Identification of ras oncogene mutations in the stool of patients with curable colorectal tumors. Science 1992;256:102-5.
37. Smith-Ravin J, England J, Talbot IC, et al. Detection of c-Ki-ras mutations in faecal samples from sporadic colorectal cancer patients. Gut 1995;36:81-6.
38. Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. Cell 1996;87:159-70.
39. Tahara E. Genetic alterations in human gastrointestinal cancers. The application to molecular diagnosis. Cancer 1995;75:1410-17.
40. Tahara E, Sumiyoshi H, Hata J, et al. Human epidermal growth factor in gastric carcinoma as a biologic marker of high malignancy. Jpn J Cancer Res 1986;77:145-52.
41. Caldas C, Hahn SA, Hruban RH, et al. Detection of K-ras mutations in the stool of patients with pancreatic adenocarcinoma and pancreatic ductal hyperplasia. Cancer Res 1994;54:3568-73.
42. Field JK, Spandidos DA. The role ofras and myc oncogenes in human solid tumours and their relevance in diagnosis and prognosis. Anticancer Res 1900;10:1-22.
43. Krontiris TG, DiMartino NA, Colb M, et al. Unique allelic restriction fragments of the human Ha-ras locus in leukocyte and tumour DNAs of cancer patients. Nature 1985;313:369-74.
44. Krontiris TG, Devlin B, Karp DD, et al. An association between the risk of cancer and mutations in the HRASI minisatellite locus. N Engl J Med 1993;329:517-23.
45. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244:707-12.
46. Roth JA. Molecular events in lung cancer. Lung Cancer 1995;2:S3-S15.
47. Mountain CF. New prognostic factors in lung cancer. Biologic prophets of cancer cell aggression. Chest 1995; 108:246-54.
48. Viallet J, Minna JD. Dominant oncogenes and tumor suppressor genes in the pathogenesis of lung cancer. Am J Respir Cell Mol Biol 1990;2:225-32.
49. Slebos RJ, Kibbelaar RE, Dalesio O, et al. K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. N Engl J Med 1990;323:561-5.
50. Heighway J, Thatcher N, Cerny T, et al. Genetic predisposition to human lung cancer. Br J Cancer 1986;53:453-7.
51. Watson JV, Stewart J, Evan GI, et al. The clinical significance of flow cytometric c-myc oncoprotein quantitation in testicular cancer. Br J Cancer 1986;53:331-7.
52. Brodeur GM, Fong CT. Molecular biology and genetics of human neuroblastoma. Cancer Genet Cytogenet 1989;41:153-74.
53. Goodfellow PJ. Inherited cancers associated with the RET proto-oncogene. Curr Opin Genet Dev 1994;4:446-52.
54. Eng C, Smith DP, Mulligan LM, et al. Point mutation within the tyrosine kinase domain of the RET proto-oncogene in multiple endocrine neoplasia type 2B and related sporadic tumours. Hum Mol Genet 1994;3:237-41.
55. Mak YF, Ponder BA. RET oncogene. Curr Opin Genet Dev 1996;6:82-6.